NEW YORK, Jan. 28--Genome Therapeutics and Singapore's MerLion Pharmaceuticals have begun joint research to identify natural products with antibacterial properties, the two companies said today.
MerLion, which is a privately owned spinoff of the privatized Centre for Natural Product Research of the Singapore Institute of Molecular and Cell Biology, will provide a large library of natural products for screening.
Genome Therapeutics, which is based in Waltham, Mass., will supply its portfolio of validated pathogenic targets.
MerLion Pharma will use Genome Therapeutics assays to identify chemicals with antibacterial properties that may be valuable as drugs.
Research will be overseen by a joint committee from both companies.
The two companies will share development costs and rights to clinical development and commercialization of drug candidates.